CarePlix is a digital health technology company that is redefining healthcare through AI-powered, device-less innovation. The company delivers an integrated suite of intelligent platforms that enable real-time vital sign monitoring, preventive screenings, and personalized health insights, directly through smartphones and web interfaces. By eliminating the need for dedicated medical hardware, CarePlix expands access while preserving clinical precision.
Its solutions empower clinicians, enterprises, insurers, and individuals alike. Specifically, CarePlix enhances quality of care, optimizes clinical and operational workflows, and improves health outcomes, while simultaneously reducing costs. Moreover, its comprehensive ecosystem integrates AI care agents, advanced clinical workflow automation, and a unified digital marketplace that seamlessly connects users with doctors, diagnostic laboratories, and wellness service providers. With a growing global footprint and millions of completed screenings, CarePlix is accelerating the shift toward proactive, preventive, and accessible healthcare at scale.
In an exclusive interaction with The Interview World at the India AI Impact Expo 2026, Subhabrata Paul, Co-founder and CIO of CarePlix, provides detailed insights into the company’s healthcare solutions. He underscores the clinically validated accuracy of CarePlix’s non-invasive diagnostic reports and explains the advanced capabilities of the Loop smart ring. The following are the key takeaways from this in-depth and thought-provoking discussion.
Q: Can you provide a comprehensive overview of the healthcare solutions offered by CarePlix?
A: CarePlix is developing a Software as a Medical Device (SaMD) platform designed to convert everyday smartphones into clinically validated pre-screening tools. We chose this path deliberately. After all, more than 90 percent of the global population uses a smartphone. However, most individuals neither own nor consistently use medical devices such as blood pressure monitors or pulse oximeters. Therefore, we asked a fundamental question: why not transform the smartphone itself into a medical-grade screening instrument?
Accordingly, we built a non-diagnostic, AI-powered pre-screening solution. Using only the smartphone camera, the system performs a 60-second facial scan and generates key physiological parameters, including heart rate, blood pressure, heart rate variability (HRV), SpO₂, stress levels, and a diabetes control score. In addition, we conduct pulmonary screening through voice biomarker analysis. Users provide a sustained vowel sound, and a voluntary cough sample. Based on these acoustic signatures, the system assesses the likelihood of obstructive airway conditions.
This approach addresses two critical gaps. First, it expands awareness by making health screening frictionless. Second, it removes dependency on multiple physical devices, which are often expensive, inconvenient, or impractical to carry. A blood pressure monitor cannot accompany a person everywhere. A smartphone, by contrast, can. Consequently, users can conduct screenings anytime, anywhere, without logistical barriers.
Technologically, our foundation rests on photoplethysmography (PPG) and remote photoplethysmography (rPPG). We initiated research in this domain in 2017. After rigorous validation and development, we launched the product commercially in 2020. Timing proved pivotal. During the COVID-19 pandemic, pulse oximeters became scarce and were frequently sold at inflated prices. In response, we released our application free of charge, prioritizing public health over immediate commercial gain. Within three months, the platform attracted more than three million users. That inflection point marked the beginning of our scale trajectory.
Today, CarePlix partners with leading insurance companies and healthcare providers. Notably, Philips, one of the world’s largest health technology companies and a pioneer in PPG-based medical devices, counts among our clients. Their trust underscores both the scientific credibility and clinical reliability of our Software as a Medical Device platform.
Q: How does your platform create value for insurance companies as well as policyholders?
A: We collaborate extensively with pharmaceutical companies that conduct large-scale population screenings. Through our platform, they generate high-volume, structured health data, which they subsequently use for clinical research and population-level assessments. As a result, our technology strengthens evidence generation while improving screening efficiency at scale.
That said, we do not provide medical diagnoses. While our system generates quantified health parameters and risk indicators, the final clinical determination always rests with a licensed physician. Accordingly, we position our platform as a pre-screening and risk stratification tool. We identify potential red flags, notify users of elevated risk, and recommend appropriate next steps, typically a formal clinical evaluation.
In practice, this creates a clear continuum of care. First, we inform individuals who may be unaware of their underlying health status. Next, we guide them toward professional medical consultation where necessary. Finally, we enable them to act on validated insights to improve their health outcomes.
In essence, our approach follows a structured progression: understand your health, assess your risk, and then take informed action to improve it.
Q: What is the validated accuracy rate of your diagnostic model?
A: Our product has undergone multiple clinical trials and validation studies. We began systematic data collection in 2017, partnering with government hospitals across India and extending our validation efforts to the United States. Consequently, we built a robust, multi-geography clinical dataset to substantiate performance and reliability.
From a regulatory perspective, we have secured critical certifications. Notably, we are the only company in India to obtain a Class B medical device license from the Central Drugs Standard Control Organization (CDSCO). In addition, we hold a US FDA Class I registration, which authorizes our platform for use as a general wellness device in the United States.
Taken together, these clinical validations and regulatory clearances reinforce the scientific integrity of our platform. Across product modules, the aggregated accuracy stands at approximately 93 percent, reflecting consistent performance under controlled evaluation conditions.
Q: Could you provide a detailed overview of the Loop smart ring?
A: Loop by CarePlix is a precision-engineered smart ring designed for continuous, unobtrusive health monitoring. Unlike a smartwatch worn on the wrist, Loop fits seamlessly on the finger and weighs just four grams. Despite its minimal form factor, it delivers comprehensive physiological tracking throughout the day.
The device monitors core health metrics, including vital parameters and step count. However, its strongest capability lies in advanced sleep analytics. Loop accurately tracks sleep architecture—covering REM sleep, deep sleep, light sleep, and overall sleep cycles, with high fidelity. As a result, users gain granular insights into sleep quality and recovery patterns.
Equally important, Loop addresses a practical limitation of wrist-based wearables. Many users find smartwatches uncomfortable during sleep or unsuitable for activities such as swimming. In contrast, Loop’s ultra-lightweight design enables uninterrupted wear, whether in bed or in water. Therefore, users benefit from continuous data capture without compromising comfort.
Beyond functionality, Loop embodies minimalist design. It integrates health intelligence into a sleek accessory, thereby combining performance with personal style.
